https://www.pnas.org/content/115/10/2329
Maybe this one which is basically saying that the NIH backed drugs and treatements tend to be first class and invariably endorsed by the FDA.
The NIH would not be backing this trial unless they thought it had serious merit. The FDA's GvHD turnover of ODAC was amateur. As others pointed out, with the NIH backing this it absolutely cannot happen if efficacy is clearly shown.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-366
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |